- Policy & Regulation
- Regulatory Trackers
- European Performance Tracker
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From BioGene Ltd
The US FDA is set for two high-profile advisory committee meetings on potential ALS treatments before the end of 2022. Whatever the outcome, they will fit a pattern: when it comes to ALS treatments, there is very little about the regulatory process that feels routine.